𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix

✍ Scribed by Gregory P. Sutton; John A. Blessing; Leon Adcock; Kenneth D. Webster; Timothy DeEulis

Publisher
Springer US
Year
1989
Tongue
English
Weight
223 KB
Volume
7
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-hodgkin's lymphoma: Cancer and leukemia group b study 8552
✍ Delvyn C. Case JR; James Anderson; Thomas J. Ervin; Arlan Gottlieb πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 522 KB

## Abstract Ifosfamide (1Β·25 g/m^2^ intravenously/day Γ— 5) with mesna (20 per cent of the ifosfamide dose Γ— six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rat

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day Γ— 3) with mesna (400 mg/m^2^ intravenously q 4 h daily Γ— 3) was combined with mitoxantrone (14 mg/m^2^ intravenously Γ— 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients

Phase II study of ifosfamide with mesna
Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma
✍ T. E. Elliott; J. C. Buckner; T. L. Cascino; R. Levitt; J. R. O'Fallon; B. W. Sc πŸ“‚ Article πŸ“… 1991 πŸ› Springer US 🌐 English βš– 318 KB

Sixteen patients who developed CT or MRI scan evidence of recurrent diffuse astrocytoma after radiation therapy and nitrosourea-containing chemotherapy received ifosfamide (2500 mg/m2/day for 3 consecutive days) and mesna (500mg/m2/dose, 5 doses/day for 3 consecutive days). Toxicity consisted primar